Genprex, Inc. announced that it received a patent from the Singapore Patent Office for its lead drug Reqorsa, which covers its use with anti-PD-1 antibodies until 2037, expanding its patent portfolio in several countries and supporting its Acclaim-3 clinical trial for small cell lung cancer.